{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:22Z","timestamp":1791924442160,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015612","name":"CancerFree KIDS","doi-asserted-by":"publisher","award":["810753-1222-00"],"award-info":[{"award-number":["810753-1222-00"]}],"id":[{"id":"10.13039\/100015612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011500","name":"Research Institute, Nationwide Children's Hospital","doi-asserted-by":"publisher","award":["AWD00001677"],"award-info":[{"award-number":["AWD00001677"]}],"id":[{"id":"10.13039\/100011500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011500","name":"Research Institute, Nationwide Children's Hospital","doi-asserted-by":"publisher","award":["45306-0015-1222"],"award-info":[{"award-number":["45306-0015-1222"]}],"id":[{"id":"10.13039\/100011500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bneo.2024.100032","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:09:23Z","timestamp":1722427763000},"page":"100032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies"],"prefix":"10.1016","volume":"1","author":[{"given":"Ella","family":"Troy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7364-5911","authenticated-orcid":false,"given":"Yasemin","family":"Sezgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo S. F.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-3607","authenticated-orcid":false,"given":"Gregory","family":"Behbehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lyberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-1796","authenticated-orcid":false,"given":"Meisam","family":"Naeimi Kararoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bneo.2024.100032_bib1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.bneo.2024.100032_bib2","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.bneo.2024.100032_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.bneo.2024.100032_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bneo.2024.100032_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100032_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-shelf CAR-NK cells for cancer immunotherapy","volume":"23","author":"Siegler","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.bneo.2024.100032_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21147\/j.issn.1000-9604.2018.02.02","article-title":"Tumor immunotherapy: new aspects of natural killer cells","volume":"30","author":"Li","year":"2018","journal-title":"Chin J Cancer Res"},{"issue":"61","key":"10.1016\/j.bneo.2024.100032_bib8","doi-asserted-by":"crossref","first-page":"31797","DOI":"10.18632\/oncotarget.25737","article-title":"Stromal CD38 regulates outgrowth of primary melanoma and generation of spontaneous metastasis","volume":"9","author":"Ben Baruch","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bneo.2024.100032_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.ai.2020.01.002","article-title":"Unraveling the mysteries of plasma cells","volume":"146","author":"Schuh","year":"2020","journal-title":"Adv Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100032_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100032_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1010428319837138","article-title":"The metabolic milieu in melanoma: role of immune suppression by CD73\/adenosine","volume":"42","author":"Passarelli","year":"2019","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100032_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100032_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.bneo.2024.100032_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: a review of its use in multiple myeloma","volume":"16","author":"Frampton","year":"2021","journal-title":"Target Oncol"},{"issue":"21","key":"10.1016\/j.bneo.2024.100032_bib15","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100032_bib16","doi-asserted-by":"crossref","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","author":"Somanchi","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.bneo.2024.100032_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-3684-7_15","article-title":"Ex\u00a0vivo expansion of human NK cells using K562 engineered to express membrane bound IL21","volume":"1441","author":"Somanchi","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100032_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex\u00a0vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bneo.2024.100032_bib19","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi","year":"2022","journal-title":"Cell Rep Methods"},{"issue":"16","key":"10.1016\/j.bneo.2024.100032_bib20","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.bneo.2024.100032_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.bneo.2024.100032_bib22","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex\u00a0vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bneo.2024.100032_bib23","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.bneo.2024.100032_bib24","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.3390\/ijms22168996","article-title":"T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bneo.2024.100032_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"Faculty Rev","key":"10.1016\/j.bneo.2024.100032_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.22257.1","article-title":"Treatment approaches in relapsed or refractory peripheral T-cell lymphomas","volume":"9","author":"Foster","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.bneo.2024.100032_bib27","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.bneo.2024.100032_bib28","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2024.100032_bib29","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100032_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2024.100032_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-021-01374-y","article-title":"GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer\/T cell lymphoma","volume":"20","author":"Rong","year":"2021","journal-title":"Mol Cancer"},{"issue":"11","key":"10.1016\/j.bneo.2024.100032_bib32","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2024.100032_bib33","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2024.100032_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat Biotechnol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T01:17:11Z","timestamp":1756257431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950328024000323"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100032","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100032"}}